Read the latest Washington Business Journal article highlighting Immunomic Therapeutics by clicking the link below: https://www.bizjournals.com/washington/news/2022/03/17/immunomic-therapeutics-expanding-hiring-pre-ipo.html
February 11, 2022 08:00 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy announced today ...
February 07, 2022 01:48 PM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP (Lysosome Associated Membrane Protein) -mediated nucleic ...
BIOTECH SHOWCASE: THE INVESTOR CONFERENCE FOR INNOVATORS ITI will be presenting at Biotech Showcase virtually, click here to view the presentation given by our CBO, Mr. Bob Newman In-person ...
January 06, 2022 12:05 PM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy announced today ...
ITI will be attending the Society for Neuro-Oncology Annual Meeting organized by SNO in Tampa, Florida, November 16-20, 2022.
ITI will be attending SITC 2022 in Boston, MA The Society for Immunotherapy of Cancer (SITC) Annual Meeting & Pre-Conference Programs brings together stakeholders across the cancer immunotherapy field to advance ...
BIO is thrilled to be back in person for the 2022 International Convention happening in San Diego, CA June 13-16. The Convention theme ‘LIMITLESS’ is our commitment to unlocking possibilities for our ...
ITI will be virtually attending The 40th Annual Health Care Conference that will take place on January 10-13, 2022 at the Westin St. Francis in San Francisco, CA. This premier ...
ITI will be attending the 2nd International Symposium on Merkel Cell Carcinoma. The focus of this symposium is to explore emerging data that may allow improvements in clinical guidelines, develop ...
2022 BIO CEO & Investor Conference: Hybrid Event ITI will be presenting at BIO CEO & Investor Conference virtually, stay tuned for more details. For more than 20 years, the ...
November 30, 2021 02:01 PM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy, announced the opening ...